



Universiteit
Leiden

The Netherlands

Recurrent glioblastoma in the era of molecular diagnostics: practice variation and practical implications

Opijnen, M.P. van

Citation

Opijnen, M. P. van. (2026, January 7). *Recurrent glioblastoma in the era of molecular diagnostics: practice variation and practical implications*. Retrieved from <https://hdl.handle.net/1887/4286054>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4286054>

Note: To cite this publication please use the final published version (if applicable).

Recurrent glioblastoma in the era of molecular diagnostics

Practice variation and practical implications

1. Two main factors can be identified to explain the variability in treatment decisions: the lack of guidelines/large prospective studies, and the concept of noise. – *this thesis*
2. Practice variation in the application of next generation sequencing for patients with high-grade glioma could possibly result in diagnostic variability and delayed diagnosis. – *this thesis*
3. In order to move the field of neuro-oncology into the direction of personalized medicine and to bridge the knowledge gap, an intensification of genome-driven trials is needed. – *this thesis*
4. Routine WGS analysis is feasible, fast and generates a large amount of genomic information on potentially actionable variants. – *this thesis*
5. Overall, molecular testing of targets for non-approved and experimental treatments should principally be considered when standard treatments have been exhausted for the respective tumor type. – *Capper et al., Neuro-Oncology, 2023*
6. At glioblastoma recurrence, standards of care are less well defined. [...] When available, recruitment into appropriate clinical trials should be considered. – *EANO guideline, Nature Reviews Clinical Oncology, 2020*
7. The acting on potentially druggable targets is challenged by target credentialing and validation, tumor heterogeneity and clinical trial design. – *Hyman et al., Cell, 2017*
8. One must decide whether one's fears or one's hopes are what should matter most. – *naar Atul Gawande, Being Mortal, 2014*
9. 'De grote verwezenlijkingen ontstaan uit de som van dagelijkse inspanningen.' Zonder zicht op het eerste is men geroepen tot het tweede. – *naar Albert Schweitzer*
10. 'Onbekend maakt onbemind.' De academische en wetenschappelijke werelden zijn, haast paradoxaal genoeg, met hun eigen handelen niet altijd in staat dit aforisme te ontcrachten. – *breed toepasbaar gezegde*
11. Promoveren met slechts intelligentie en zonder doorzettingsvermogen is als het zetten van een goede espresso zonder vers gebrande bonen: bij voorbaat kansloos.